PDS0101 Phase 2 Data in JAMA Oncology Shows 39.3-Month Survival in Head and Neck Cancer
PDSB has more than doubled off its 52-week low of $0.195.
Summary
PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology showing a 39.3-month median overall survival for PDS0101 plus pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer, versus 17.9 months for standard of care. The 36% objective response rate also compares favorably to 19% for pembrolizumab alone. This peer-reviewed publication validates the drug's efficacy, but the company has already deprioritized PDS0101 in favor of PDS0301 and is seeking a partner for further development. The data could strengthen partnership negotiations, though the company's cash position remains tight at $5.6M with a going concern warning. The stock trades below $1, facing Nasdaq delisting risk.
At the time of this announcement, PDSB was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.1M. The 52-week trading range was $0.20 to $1.55. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.